← Back to Search

Unknown

SAD Cohorts 1 to 2: Participants receiving ECC4703 for Fatty Liver Disease

Phase < 1
Waitlist Available
Research Sponsored by Eccogene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up sad: up to day 8 and mad: up to day 21.

Summary

This trial tests a new drug called ECC4703 in healthy people and those with slightly elevated cholesterol. It aims to see how the drug is processed by and affects the body.

Eligible Conditions
  • Fatty Liver Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~sad: up to day 8 and mad: up to day 21.
This trial's timeline: 3 weeks for screening, Varies for treatment, and sad: up to day 8 and mad: up to day 21. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Electrocardiogram
Secondary study objectives
Pharmacodynamic assessment: ApoB
Pharmacodynamic assessment: Glucose
Pharmacodynamic assessment: HDL-C
+25 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: SAD Cohorts 1 to 2: Participants receiving ECC4703Experimental Treatment1 Intervention
Participants in each SAD cohort will be randomized to receive up to 4 escalating doses (1 mg, 4 mg, 12 mg, 32 mg, 80 mg, 160 mg, 320 mg or 400 mg).
Group II: MAD Cohorts 1 to 4: Participants receiving ECC4703Experimental Treatment1 Intervention
Participants will be randomized to receive a once-daily dose of 1 of 3 escalating doses (40 mg, 80 mg, or 160 mg) for 14 days.
Group III: SAD Cohorts 1 to 2: Participants receiving PlaceboPlacebo Group1 Intervention
Participants in each SAD cohort will be randomized to receive placebo
Group IV: MAD Cohorts 1 to 4: Participants receiving PlaceboPlacebo Group1 Intervention
Participants will be randomized to receive a once-daily dose of placebo for 14 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ECC4703
2022
Completed Early Phase 1
~80

Find a Location

Who is running the clinical trial?

EccogeneLead Sponsor
4 Previous Clinical Trials
220 Total Patients Enrolled
~23 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top